Saxagliptin antidiabetic drugs
systematic review meta-analysis network meta-analysis
 

BMS-477118 - BMS477118 - BMS 477118 - Onglyza - saxagliptin      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultcardiovascular eventsCardiovascular death

diabetes type 2  

Kawamori, 2012        NCTsaxagliptin -
Forst, 2011   Saxagliptin -
Fonseca, 2012      NCTsaxagliptin -
Nowicki, 2011      NCTsaxagliptin -
Yang, 2011      NCTsaxagliptin -
Nowicki, 2011      NCTsaxagliptin -
Göke, 2010     saxagliptin -
Scheen , 2010     saxagliptin -
Stenlöf , 2010     Saxagliptin -
CV181-040      NCTsaxagliptin + glyburideglyburide uptitration -
CV181-085    NCTsaxagliptin plus metformin XR 1500mgmetformin up to 2000mg -
SAVOR-TIMI 53, 2013        NCTsaxagliptinplacebonegative 0%3%
SAVOR TIMI, 2013      NCTsaxagliptinplaceboLow risk of bias negative0%3%
saxgliptin, renal study   saxagliptinplacebo (add on current treatment) -
CV181-057    NCTsaxagliptinplacebo (add on insulin) -
DeFronzo, 2009      NCTsaxagliptinplacebo (add on MET)negative
Jadzinsky, 2009      NCTsaxagliptinplacebo (add on MET) -
CV181-066    NCTsaxagliptinplacebo (add on MET) -
CV181-080    NCTsaxagliptinplacebo (add on MET) -
Hollander      NCTsaxagliptinplacebo (add on TZD) -
Rosenstock, 2008    NCTsaxagliptinplacebo (monotherapy) -
CV181-011      NCTsaxagliptinplacebo (monotherapy) -
CV181-038    NCTsaxagliptinplacebo (monotherapy) -
CV181-041    NCTsaxagliptinplacebo (monotherapy) -
saxagliptin vs sitagliptin   saxagliptinsitagliptin (add on MET) -
saxagliptin   saxagliptinglipizideLow risk of bias -



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons